Min.Order / FOB Price:Get Latest Price
1 Gram |
Negotiable |
Bimatoprost supplier Bimatoprost manufacturer 155206-00-1
Bimatoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. Bimatoprost is manufactured at Cayman Pharma, our Czech subsidiary. The DMF is on file with the US FDA, Canada, and India.
Bimatoprost is a synthetic amide F2α derivative ,it can selectively simulate the effect forefront amines produced by the body, which make aqueous humor production rate increase aqueous outflow resistance is reduced, by increasing the amount of aqueous outflow of the uveoscleral and trabecular Netcom channel to reduce intraocular pressure (IOP),it is considered to be the most effective hypotensive drug of topical ocular anti-glaucoma drugs,it is suitable for the treatment of open-angle glaucoma (POAG) or invalid elevated intraocular other ocular hypotensive medications compression syndrome (OHT) patients.
A potent prostanoid receptor (FP) agonist and PGF2α analog. Its biological activity is mediated by action on prostamide receptors. Has therapeutic potential for glaucoma and ocular hypertension.
Catalogue Number | B386800 |
Chemical Name | Bimatoprost |
Synonyms | (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide; AGN-192024; Lumigan; Prostamide; |
CAS Number | 155206-00-1 |
Molecular Formula | C??H??NO? |
Appearance | White to Off-White Solid |
Melting Point | 64 - 65°C |
Molecular Weight | 415.57 |
Storage | Amber Vial, -20°C Freezer, Under Inert Atmosphere |
Solubility | Chloroform (Slightly), Dichloromethane (Slightly), Methanol (Slightly) |
Stability | Light Sensitive |
Category | Standards; Chiral Molecules; Pharmaceutical/API Drug Impurities/Metabolites; |
Applications | Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α. |
Glaucoma Drug |
Bimatoprost is a synthetic amide F2α derivative ,it can selectively simulate the effect forefront amines produced by the body, which make aqueous humor production rate increase aqueous outflow resistance is reduced, by increasing the amount of aqueous outflow of the uveoscleral and trabecular Netcom channel to reduce intraocular pressure (IOP),it is considered to be the most effective hypotensive drug of topical ocular anti-glaucoma drugs,it is suitable for the treatment of open-angle glaucoma (POAG) or invalid elevated intraocular other ocular hypotensive medications compression syndrome (OHT) patients. |
Side effects |
1. to deepen the color of the iris, blepharitis, eye irritation and pain; black eyelashes thicker growth; conjunctival hyperemia, temporarily punctate corneal epithelial erosion, eyelid edema and erythema; rash. 2. rare respiratory disorders, asthma exacerbations, iritis, uveitis, eyelid skin darkening. 3. very rare chest pain, pharyngitis. 4. eye itching, allergic conjunctivitis, cataract, conjunctival edema, secretions, photophobia, superficial punctate keratitis, headache, high blood pressure. |
Glaucoma commonly used drugs |
1. prostaglandin derivatives such as latanoprost (Xalatan), bimatoprost (trade name Lumigan) and travoprost (Travatan) can increase outflow of aqueous humor uveoscleral . Bimatoprost also increases trabecular outflow. 2. topical β-adrenergic such as timolol, levobunolol (Betagan), and betaxolol can decrease receptor antagonist of aqueous humor production of ciliary body . 3. Alpha2-adrenergic agonists such as brimonidine (Alphagan) with dual working mechanism, can reduce aqueous humor production and increase trabecular outflow. 4. one case of the selective reduction similar to epinephrine and dipivefrin (Propine) increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway, probably by a β2-agonist action. 5. miotic agents (parasympathomimetics), if ciliary muscle contraction Roca works, it can tighten the trabecular and allow increaseing outflow of aqueous humor. Ecothiopate is used for chronic glaucoma. 6. dorzolamide (Trusopt), brinzolamide (Azopt), by inhibiting carbonic anhydrase acetazolamide of ciliary body, reduce aqueous humor secretion of carbonic anhydrase inhibitors. 7. Physostigmine is also used to treat glaucoma and delayed gastric emptying. The above information is edited by the lookchem of Tian Ye. |
Bimatoprost - timolol maleate compound eye drops |
In July 2006 , bimatoprost-timolol maleate compound eye drops developed by the United States company obtained approval from the European drug regulatory authority for reducing intraocular pressure or ocular hypertension of open-anglepatients glaucoma patients who do not respond adequately to the β-blockers or prostaglandin like treatment . The compound eye drops containing 0.03% bimatoprost and 0.5% timolol maleate, once a day administration is able to provide clinically effective pressure control, the effect is better than single Bima latanoprost or timolol maleate. Clinical trials prove that the drug has an excellent tolerability, including the incidence of ocular hyperemia40% lower compared to single bimatoprost . |
Brand name |
Lumigan (Allergan). |
General Description |
Bimatoprost (Lumigan) is supplied as a sterile 0.03%ophthalmic solution in 2.5- and 5.0-mL sizes. The recommendeddosage of bimatoprost is limited to one drop intothe affected eye once daily in the evening. Increased usagemay decrease its beneficial effect. If used concurrently withother IOP-lowering drugs, a waiting period of 5 minutesshould separate administrations. |
InChI:InChI=1/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3+,17-16+/t20-,21+,22+,23-,24+/m0/s1
A simple, convenient and efficient synth...
The invention discloses a preparation me...
A new protocol for the construction of a...
The present invention relates to a proce...
Provided is a novel method for preparing...
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide
bimatoprost
Conditions | Yield |
---|---|
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 20 ℃; for 4h; Reagent/catalyst; Temperature; Inert atmosphere;
|
80% |
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h;
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; In tetrahydrofuran; at 0 ℃;
|
65% |
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 0 - 20 ℃; for 1h; Inert atmosphere;
|
41% |
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 1h;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at -17 ℃; for 20.5h;
|
|
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Schlenk technique; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 20 ℃; for 1h; Schlenk technique; Inert atmosphere;
|
82.6 mg |
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 0 - 20 ℃; for 2h; Inert atmosphere;
|
108 mg |
(5Z)-N-ethyl-7-((1R,2R,3R,5S)-5-hydroxy-2-((3S,E)-5-phenyl-3-(tetrahydro-2H-pyran-2-yloxy)pent-1-enyl)-3-(tetrahydro-2H-pyran-2-yloxy)cyclopentyl)hept-5-enamide
bimatoprost
Conditions | Yield |
---|---|
With toluene-4-sulfonic acid; In methanol; at 20 ℃; for 2h;
|
77.5% |
With toluene-4-sulfonic acid; In methanol; at 20 ℃; for 2h;
|
77.5% |
ethylamine
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-(E)-3-hydroxy-5-phenylpent-1-enyl)-cyclopentyl]hept-5-enoic acid methyl ester
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol
propylamine
C29H41NO7
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E)-3-oxo-5-phenylpent-1-en-1-yl]cyc!opentyl}-N-ethylhept-5-enamide
(1R,2R,3R,4S)-3-[(2Z)-7-(ethylamino)-7-oxohept-2-en-1-yl]-4-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl 4-bromobutanoate
4-chlorobutyl (2R,3R)-3-[(2Z)-7-(ethylamino)-7-oxohept-2-en-1-yl]-4-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl carbonate
CAS NO:488-69-7
CAS NO:83-44-3
CAS NO:136-47-0
CAS NO:5086-74-8
CAS NO:831217-01-7
CAS NO:66-84-2
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View